Suki vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Suki ambient AI scribe serves 400+ health systems (4x growth in 2024), generates $1,223/month incremental revenue per provider; raised $168M including $70M Series D and Zoom Ventures (2024).
About
Suki is an AI-powered healthcare technology company founded in 2017 by Punit Soni (ex-Google/Motorola VP), headquartered in Redwood City, California. Its AI scribe listens to clinician-patient conversations and auto-generates structured notes, coding suggestions, and clinical orders. Raised $168M total including a $70M Series D (October 2024) and Zoom Ventures investment (January 2025).
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.